Evidence map›Paper›PMID 26691754›Full record

ArticleNeuroreport2016

Decreased expression of cortactin in the schizophrenia brain.

Hriday P Bhambhvani, Micah Simmons, Vahram Haroutunian, James H Meador-Woodruff

Open access · greenAbstract read
In one paragraph

Article in Neuroreport, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cortactin Is a Regulator of Activity-Dependent Synaptic Plasticity Controlled by Wingless.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hriday P BhambhvaniaDepartment of Psychiatry and Behavioral Neurobiology bUniversity Honors Program, University of Alabama at Birmingham, Birmingham, Alabama cDepartment of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA.
Micah Simmons
Vahram Haroutunian
James H Meador-Woodruff
Behavioral Pharma (United States) · US

Funding

White Matter Abnormalities in SchizophreniaP50MH066392 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BUXBAUM, JOSEPH D. · 2002 to 2012
$18.6M
Subcellular Glutamate Receptor Defects in SchizophreniaR01MH053327 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MEADOR-WOODRUFF, JAMES H · 1995 to 2015
$5.8M
Cortico-thalamic Glutamate/GABA mRNA in schizophreniaR01MH064673 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HAROUTUNIAN, VAHRAM · 2003 to 2012
$3.4M
NIMH NIH HHS MH064673NIMH NIH HHS MH066392NIMH NIH HHS MH53327NIMH NIH HHS P50 MH066392NIMH NIH HHS R01 MH053327NIMH NIH HHS R01 MH064673
6 · The paper itself

Abstract

Schizophrenia is a severe psychiatric disorder that is characterized by a wide array of symptoms and a complex neuropathology. A well-characterized neurobiological feature of schizophrenia is abnormal synaptic plasticity, although the mechanisms underlying this are not fully understood. Numerous studies have demonstrated a link between proper functioning of the cytoskeleton and synaptic plasticity. The actin-related protein-2/3 (Arp2/3) complex is responsible for the nucleation of new actin filaments and elongation of existing actin filaments and is thus crucial to cytoskeletal dynamics, especially actin polymerization and organization. To determine whether the Arp2/3 complex is abnormally expressed in schizophrenia, we measured the protein expression of Arp2 and Arp3, as well as Arp2/3 complex binding partners and associated proteins including cortactin, neuronal-Wiskott-Aldrich syndrome protein (WASP), WASP-family verprolin homologous protein 1 (WAVE1), and Abelson interactor 1 (Abi1) in the superior temporal gyrus of paired schizophrenia and comparison participants. No changes were found in Arp2, Arp3, neuronal-WASP, WAVE1, or Abi1. However, all three isoforms of cortactin were decreased in schizophrenia. Specifically, the 62 kDa isoform was decreased by 43%; the 71 kDa isoform was decreased by 32%; and the 58 kDa isoform was decreased by 35%. Cortactin regulates branching of filamentous actin through its binding and activation of the Arp2/3 complex, and it is thus critical to the formation of stable actin networks. These findings contribute to a growing body of evidence implicating altered cytoskeletal dynamics in schizophrenia.

Indexed as

Tissue BanksActin-Related Protein 2Actin-Related Protein 2-3 ComplexActin-Related Protein 3Adaptor Proteins, Signal TransducingAgedAged, 80 and overCortactinCytoskeletal ProteinsFemaleHumansMaleSchizophreniaTemporal LobeWiskott-Aldrich Syndrome ProteinWiskott-Aldrich Syndrome Protein FamilyABI1 protein, humanActin-Related Protein 2Actin-Related Protein 2-3 ComplexActin-Related Protein 3ACTR2 protein, humanACTR3 protein, humanAdaptor Proteins, Signal TransducingCortactinCTTN protein, humanCytoskeletal ProteinsWASF1 protein, humanWAS protein, humanWiskott-Aldrich Syndrome ProteinWiskott-Aldrich Syndrome Protein Family

Identifiers

PMID26691754
PMCPMC4733612
OpenAlexW2428886369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.